As per the report published, the size of the Antifungal Drugs Market in North America is estimated at $4.97 billion in 2019 and projected to be growing with CAGR of 3.7% reaching $5.96 billion by 2024. In the following years, the market is poised to grow significantly with the rising global population.
Antifungal drugs are used commonly for curing fungal infections occurring due to, unclean, unhygienic and damp environments. Invasion of epithelial tissue by microscopic organisms leads to fungal infections. Systemic fungal infections are those caused due to indigestion or inhalation of spores, leading to fungal pneumonia and diseases like candidiasis, meningitis, mucormycosis, etc. are caused by opportunistic fungus. Although the majority of the fungal infections and diseases are commonly non-lethal, they are very uncomforting to the host and their common occurrence is responsible for the rising antifungal drugs market. Antifungal drugs work via various mechanisms such as by inhibiting cell wall formation, cell membrane disruption, and cell division.
The major factors driving the market are rising awareness of fungal infections with more and more cases of antifungal infections all over the world, an increase in government and corporate funding in the industry. Further, the growing public-private partnership in the pharmaceutical industry and the mounting popularity of over-the-counter antifungal drugs to cure dermal infections are responsible for the growth of North America antifungal drugs market. Also, the rising population with weak immune systems because of cancer chemotherapy or acquired immunodeficiency syndrome, in whom the fungal infections occur more frequently than average, is driving the market in North America. Existing high penetration of conventional drugs used for the treatment of common fungal infections is restraining the market growth.
High drug costs are a challenge faced by the market. Increasing treatment effectiveness can help in overcoming it.
This research report segmented and sub-segmented into the following categories:
Geographically, North America has commanded the largest share of the global antifungal drugs market. The United States antifungal drugs market contributes to the major share of the North America antifungal drugs market due to the presence of the leading companies. Canada's antifungal drug market is expected to grow fastest in the North America region.
The major companies dominating the market are Alternaria, Pfizer, Novartis, Sanofi-Aventis, Merck & Co., Asperqillus, Kramer Laboratories, Bayer Healthcare, Enzon Pharmaceuticals, Glaxosmithkline Gilead and Abbott Laboratories to name few.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Drug Type
5.1.1 Echinocandins
5.1.2 Azoles
5.1.3 Polyenes
5.1.4 Allylamines
5.1.5 Others
5.2 By Therapeutic Indications
5.2.1 Aspergillosis
5.2.2 Dermatophytosis
5.2.3 Candidiasis
5.2.4 Others
5.3 By Application
5.3.1 Powders
5.3.2 Ointments
5.3.5 Drugs
5.3.4 Pastes
6. Geographical Analysis
6.1 Introduction
6.2 United States
6.3 Canada
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Alternaria
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Pfizer
8.3 Novartis
8.4 Sanofi-Aventis
8.5 Merck & Co.
8.6 Asperqillus
8.7 Kramer Laboratories
8.8 Bayer Healthcare
8.9 Enzon Pharmaceuticals
8.10 Glaxosmithkline Gilead
8.11 Abbott Laboratories
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
